🧾 What This Document Is

This is an 8-K filing, which is a mandatory report to the SEC that companies use to announce major news to investors. Attached is their full press release. Think of it as the company's official news bulletin, sharing their financial scorecard for 2025 and exciting updates on their progress.

🏢 What The Company Does

👉 In simple terms, Turn Therapeutics (TTRX) is a clinical-stage biotech company creating new skin treatments. Their main focus is developing a new drug, GX-03, for moderate-to-severe atopic dermatitis (a serious form of eczema). They are also exploring other applications, like a potential nasal flu vaccine, using their special drug delivery technology called PermaFusion®.

💰 Financial Highlights (2025)

The company is still in the research phase, so it's not yet profitable. Here’s the snapshot:

Net Loss: For 2025, they had a net loss of $3.19 million (compared to a loss of $1.77 million in 2024).
Cash Position: At year-end, they had $5.08 million in cash. This is important because it does NOT include the new $7 million they just received from Avenue Capital in March 2026.
Expenses:
- Research & Development (R&D): $0.3 million, roughly the same as last year.
- General & Administrative (G&A): $5.5 million, a big jump from $1.5 million. Why? ➡️ Costs related to becoming a publicly traded company, like legal and accounting fees.

🚀 Key Moves & Updates

This is the real news in the filing. Here’s what they’ve been up to:

Clinical Trial Progress: Their Phase 2 trial for GX-03 in atopic dermatitis is on track. They expect the key results (topline data) mid-2026. This is a critical milestone that will determine the drug's next steps.
Secured Major Funding: They signed a deal for up to $25 million in growth capital from Avenue Capital Group. This is a loan facility (venture debt) with a 42-month term. They've taken an initial $7 million tranche and can access more based on hitting milestones.
- 👉 Why it matters: This funding extends their financial runway through the end of 2027, giving them time to develop their lead drug without constant worry about running out of cash.
Leadership Boosts:
- Dr. Robert Redfield, former Director of the CDC, was appointed to advise on GX-03's development and regulatory path.
- Martin Dewhurst, a veteran from McKinsey & Company's life sciences practice, joined the Board of Directors to guide long-term strategy.
Commercial Partnership: They have a global agreement with Medline (a huge medical products company) to develop and sell products using their PermaFusion® technology. This could lead to first revenue in late 2026.
Pipeline Expansion: They are adding an intranasal influenza vaccine candidate to their research pipeline.

💸 Cash Flow Story & Financial Position

While their yearly loss increased, the story is about securing future cash. The big news is the $25 million facility. The initial $7 million is already in hand, which significantly improves their cash position for 2026. The loan is designed to fund operations and key clinical milestones through 2027.

🔮 What's Next

The near-term future is all about GX-03:

Complete the Phase 2 trial for atopic dermatitis.
Release the topline results in mid-2026.
Use the new funding and expert guidance from Dr. Redfield to plan the next phase of development toward potential approval.
Begin generating potential revenue from the Medline partnership.

⚖️ Big Picture

👍 Strengths:
- Well-Funded: The new $25M facility provides a clear runway to execute their plans.
- Expert-Backed: Adding a former CDC director and a top strategy consultant brings serious credibility and guidance.
- Strategic Partnership: The Medline deal validates their technology and offers a path to future revenue.
- Focused Pipeline: They have a clear lead asset (GX-03) with a defined near-term catalyst.
⚠️ Risks:
- Clinical Trial Risk: The success of GX-03 is everything. The mid-2026 results are make-or-break.
- Cash Burn: They are still losing money ($3.2M in 2025) and are reliant on clinical and commercial success to become sustainable.
- Development Hurdles: Getting a new drug fully approved and to market is a long, expensive, and uncertain process.

🧠 The Analogy

Think of Turn Therapeutics like a talented chef opening a new restaurant. They have a signature recipe (GX-03) they believe will be a hit. This funding round ($25M) is like getting an investor to cover the rent and ingredients for the next two years. Hiring Dr. Redfield and Martin Dewhurst is like bringing on a renowned food critic and a veteran restaurant manager as advisors. The Medline partnership is a deal to sell their special sauce in grocery stores. The big moment is mid-2026, when the first batch of customers (clinical trial patients) gets to taste the dish and decides if it's a hit or a miss.

📇 Key Contacts & People

Sasha Damouni - Investor Relations / Media Contact
- Email: [email protected]
Bradley Burnam - Chief Executive Officer
Dr. Robert Redfield - Strategic Advisor (Former CDC Director)
Martin Dewhurst - Board of Directors (Former McKinsey Life Sciences Co-Lead)

🧩 Final Takeaway

Turn Therapeutics is a well-funded, clinical-stage biotech with a critical test for its lead eczema drug coming in mid-2026. They've strengthened their cash position, leadership team, and commercial prospects, but their future success hinges entirely on positive clinical trial results for GX-03.

Turn Therapeutics Inc. — 8-K Filing